Perhaps the ideal setting to test secretory biomarkers would be in tissues/blood obtained after neoadjuvant PD-L1 inhibition, of which several trials are currently underway (recently reviewed (Topalian et al, 2023)) including in cutaneous melanoma patients treated with atezolizumab for 6 weeks (NCT04020809). Here, CD274 is linked to cutaneous melanoma.